A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma
Trial Details
- NCT ID
- NCT06566586
- Phase
- PHASE2
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- RECRUITING
- Cancer Type
- Non-Hodgkin Lymphoma Lymphoma
- Interventions
- TQB3702 tablets+Chemotherapy regimen
- Locations (sample)
- Beijing, Beijing Municipality, China|39.9075,116.39723
- Lanzhou, Gansu, China|36.05701,103.83987
- Guangzhou, Guangdong, China|23.11667,113.25
- Guigang, Guangxi, China|23.11603,109.59472
- Nanning, Guangxi, China|22.81667,108.31667
Key Eligibility Criteria
- The subjects voluntarily joined the study, signed the informed consent, and the compliance was good;
- Age: 18 years old ≤ age (when signing the informed consent) ≤75 years old; Eastern cooperative oncology group (ECOG) score: 0-2; Expected survival …
- Histologically confirmed B-cell lymphomas of the following types that meet the 2022 World Health Organization (WHO) diagnostic criteria:
- Relapsed/refractory indolent B-cell lymphoma
For full eligibility, visit ClinicalTrials.gov.